<DOC>
	<DOCNO>NCT00853827</DOCNO>
	<brief_summary>The study assess change coronary atherosclerotic disease determine intravascular ultrasound ( IVUS ) aliskiren compare placebo give addition standard therapy patient coronary artery disease ( CAD ) blood pressure pre-hypertensive range .</brief_summary>
	<brief_title>Safety Efficacy Aliskiren Progression Atherosclerosis Coronary Artery Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Patients CAD blood pressure prehypertensive range define msSBP ≥ 125 ≤ 139mmHg msDBP &lt; 90mmHg . Patients without current treatment hypertension Angiographic evidence coronary artery disease At least 2 qualify Cardiovascular risk factor Visit 1 Baseline IVUS determine unacceptable Patients require treatment disallow study medication Patients clinically significant heart disease Previous current diagnosis heart failure ( NYHA Class IV ) document left ventricular ejection fraction &lt; 25 % Patients require treatment 2 follow class medication Visit 1 Visit 2 : Angiotensin convert enzyme inhibitor Angiotensin receptor blocker aldosterone receptor blocker direct renin inhibitor . Other condition may apply</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CAD</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>coronary atherosclerosis</keyword>
	<keyword>coronary angiography</keyword>
	<keyword>IVUS</keyword>
	<keyword>intravascular ultrasound</keyword>
	<keyword>plasma renin activity</keyword>
	<keyword>renin angiotensin aldosterone system ,</keyword>
	<keyword>direct renin inhibitor</keyword>
	<keyword>coronary atheroma</keyword>
</DOC>